You are here

FDA : First-Line Nilotinib for Priority Review

sandy craine's picture
Submitted by sandy craine on Wed, 03/03/2010 - 9:02pm
I was confused by the use of the word 'slates' in this context... but I worked out that it probably means 'includes - as in 'writes on the slate' -rather than in the usual UK English meaning of to slate = to rubbish.... so 'FDA slates' is a good thing ;o)

I was confused by the use of the word 'slates' in this context... but I worked out that it probably means 'includes - as in 'writes on the slate' -rather than in the usual UK English meaning of to slate = to rubbish.... so 'FDA slates' is a good thing ;o)

Sustained MR with Interferon Alfa Maintenance After Induction Therapy With Imatinib + Interferon Alfa in CML

sandy craine's picture
Submitted by sandy craine on Thu, 11/02/2010 - 1:47pm
JCO Early Release, published online ahead of print Feb 8 2010 Journal of Clinical Oncology, 10.1200/JCO.2009.25.5075

JCO Early Release, published online ahead of print Feb 8 2010
Journal of Clinical Oncology, 10.1200/JCO.2009.25.5075

Driving away Big Pharma is not NICE or clever:

sandy craine's picture
Submitted by sandy craine on Wed, 10/02/2010 - 6:58pm
Driving away Big Pharma is not NICE or clever Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?

Driving away Big Pharma is not NICE or clever
Drug companies are not villains, they are responsible for most medical breakthroughs. So why make life hard for them?

Webcast- LLSociety. 'Current treatment Options in CML-Progress in Research'

sandy craine's picture
Submitted by sandy craine on Thu, 04/02/2010 - 12:34pm
The Leukaemia and Lymphoma Society, US, have produced another excellent webcast 'Current treatment Options in CML-Progress in Research' with the following speakers: Michael J. Mauro, MD

The Leukaemia and Lymphoma Society, US, have produced another excellent webcast 'Current treatment Options in CML-Progress in Research' with the following speakers:

Michael J. Mauro, MD

Vaccine in CML- Abstract AACRJournals

sandy craine's picture
Submitted by sandy craine on Mon, 25/01/2010 - 11:14am
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

B. Douglas Smith1, Yvette L. Kasamon1, Jeanne Kowalski1, Christopher Gocke1, Kathleen Murphy1, Carole B. Miller2, Elizabeth Garrett-Mayer3, Hua-Ling Tsai1, Lu Qin1, Christina Chia1, Barbara Biedrzycki1, Thomas C. Harding4, Guang Haun Tu4, Richard Jones1, Kristen Hege4 and Hyam I. Levitsky1

Cord blood stem cell transplant hopes lifted

sandy craine's picture
Submitted by sandy craine on Tue, 19/01/2010 - 12:34pm
Cord blood stem cell transplant - hopes lifted Matching donors cannot always be found, despite extensive registries A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.

Cord blood stem cell transplant - hopes lifted

Matching donors cannot always be found, despite extensive registries
A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.

Pages